The scientists said they expect to use a multiple test or assay approach to identify compounds that act on NTSR1, a method both believe will be an improvement over the current single assay approach typically used in the pharmaceutical industry.
"We want to avoid missing any potentially valuable compounds," McDonald noted, "so we plan to cast as wide a net as possible to capture compounds that modulate the receptor through different mechanisms."
If the team identifies compounds of interest, the scientists plan to determine their "functional fingerprint," then work with addiction experts at Scripps Florida, such as Associate Professor Paul Kenny, to help validate the compounds as potential therapeutics for addiction. Their search may ultimately move beyond addiction, however, since NTSR1 and related receptors such as NTSR2 and NTSR3 are also involved in diseases such as Alzheimer's, Parkinson's, and even some cancers.
|Contact: Miko Ono|
Scripps Research Institute